Drug Target Review

MAY 7, 2024

At Debiopharm, he has overseen both preclinical and clinical pharmacology of assets from phase I to III. He demonstrates a profound understanding of clinical research procedures (ICH GCP) and excels in interpersonal communication, fostering relationships and collaborations with key opinion leaders (KOLs).

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

Drug Target Review

SEPTEMBER 5, 2024

I am a pharmacist by training and continued with a PhD in Clinical Pharmacology. However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. As a direct consequence, in silico methods in human clinical trials are emerging as an important new paradigm in the development of medical therapies – particularly useful for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Pharma Data

OCTOBER 1, 2021

The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.

Disease 52

Disease Laboratories Clinical Pharmacology Treatment 52